Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01803321 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)
A Phase 1 study, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT01803321 is a Phase 1 study that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT01803321, a Phase 1 study, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.
Interventions
- OTHER Placebo
- DRUG rilonacept (IL-1 Trap)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01803321
The ClinicalTrials.gov registry entry for NCT01803321 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01803321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01803321 about?
NCT01803321 is a clinical study titled "Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA)". This study is a pilot, ascending dose, multi-center, randomized, double blind, placebo controlled, pediatric study conducted in three phases.
What is the current status of trial NCT01803321?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2005-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT01803321?
The interventions under investigation include: Placebo (OTHER), rilonacept (IL-1 Trap) (DRUG).
Who is sponsoring clinical trial NCT01803321?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.